Cargando…
CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
INTRODUCTION: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. METHODS: Cutoffs for Elecsys amyloid-β(1–42) (Aβ)...
Autores principales: | Hansson, Oskar, Seibyl, John, Stomrud, Erik, Zetterberg, Henrik, Trojanowski, John Q., Bittner, Tobias, Lifke, Valeria, Corradini, Veronika, Eichenlaub, Udo, Batrla, Richard, Buck, Katharina, Zink, Katharina, Rabe, Christina, Blennow, Kaj, Shaw, Leslie M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119541/ https://www.ncbi.nlm.nih.gov/pubmed/29499171 http://dx.doi.org/10.1016/j.jalz.2018.01.010 |
Ejemplares similares
-
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status
por: Palmqvist, Sebastian, et al.
Publicado: (2019) -
Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
por: Blennow, Kaj, et al.
Publicado: (2019) -
Clinical and multimodal biomarker correlates of ADNI neuropathological findings
por: Toledo, Jon B, et al.
Publicado: (2013) -
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
por: Toledo, Jon B, et al.
Publicado: (2014) -
The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort
por: Kang, Un Jung, et al.
Publicado: (2016)